Metropolitan Life Insurance Company (MetLife)’s Clovis Oncology, Inc. CLVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-16,963
| Closed | -$46K | – | 2776 |
|
|
2021
Q4 | $46K | Buy |
16,963
+2,285
| +16% | +$8.45K | ﹤0.01% | 2708 |
|
|
2021
Q3 | $65.5K | Sell |
14,678
-11,111
| -43% | -$53.5K | ﹤0.01% | 2721 |
|
|
2021
Q2 | $150K | Buy |
25,789
+2,143
| +9% | +$12.6K | ﹤0.01% | 2365 |
|
|
2021
Q1 | $166K | Sell |
23,646
-2,451
| -9% | -$16.4K | ﹤0.01% | 2148 |
|
|
2020
Q4 | $125K | Buy |
26,097
+618
| +2% | +$3.13K | ﹤0.01% | 2235 |
|
|
2020
Q3 | $149K | Buy |
25,479
+2,017
| +9% | +$12.1K | ﹤0.01% | 1966 |
|
|
2020
Q2 | $158K | Buy |
23,462
+7,912
| +51% | +$59.9K | ﹤0.01% | 1964 |
|
|
2020
Q1 | $98.9K | Hold |
15,550
| – | – | ﹤0.01% | 2037 |
|
|
2019
Q4 | $162K | Buy |
15,550
+37
| +0.2% | +$269 | ﹤0.01% | 2055 |
|
|
2019
Q3 | $61K | Hold |
15,513
| – | – | ﹤0.01% | 2479 |
|
|
2019
Q2 | $231K | Hold |
15,513
| – | – | ﹤0.01% | 1808 |
|
|
2019
Q1 | $385K | Hold |
15,513
| – | – | 0.01% | 1460 |
|
|
2018
Q4 | $279K | Hold |
15,513
| – | – | 0.01% | 1593 |
|
|
2018
Q3 | $456K | Hold |
15,513
| – | – | 0.01% | 1442 |
|
|
2018
Q2 | $705K | Buy |
15,513
+1,174
| +8% | +$57.1K | 0.01% | 1101 |
|
|
2018
Q1 | $757K | Buy |
14,339
+201
| +1% | +$11.7K | 0.01% | 1034 |
|
|
2017
Q4 | $961K | Sell |
14,138
-15,156
| -52% | -$1.06M | 0.01% | 913 |
|
|
2017
Q3 | $2.41M | Hold |
29,294
| – | – | 0.02% | 877 |
|
|
2017
Q2 | $2.74M | Buy |
29,294
+3,845
| +15% | +$235K | 0.02% | 860 |
|
|
2017
Q1 | $1.62M | Buy |
25,449
+1,883
| +8% | +$114K | 0.01% | 1030 |
|
|
2016
Q4 | $1.05M | Sell |
23,566
-798
| -3% | -$28.1K | 0.01% | 1273 |
|
|
2016
Q3 | $878K | Buy |
24,364
+318
| +1% | +$6.82K | 0.01% | 1360 |
|
|
2016
Q2 | $330K | Buy |
24,046
+4,795
| +25% | +$70.1K | ﹤0.01% | 1960 |
|
|
2016
Q1 | $370K | Hold |
19,251
| – | – | ﹤0.01% | 1775 |
|
|
2015
Q4 | $674K | Sell |
19,251
-308
| -2% | -$19.9K | 0.01% | 1431 |
|
|
2015
Q3 | $1.8M | Buy |
19,559
+1,361
| +7% | +$118K | 0.01% | 950 |
|
|
2015
Q2 | $1.6M | Sell |
18,198
-1,010
| -5% | -$86.5K | 0.01% | 1051 |
|
|
2015
Q1 | $1.43M | Hold |
19,208
| – | – | 0.01% | 1027 |
|
|
2014
Q4 | $1.08M | Hold |
19,208
| – | – | 0.01% | 1287 |
|
|
2014
Q3 | $871K | Hold |
19,208
| – | – | 0.01% | 1363 |
|
|
2014
Q2 | $795K | Buy |
19,208
+4,537
| +31% | +$234K | 0.01% | 1512 |
|
|
2014
Q1 | $1.02M | Hold |
14,671
| – | – | 0.01% | 1339 |
|
|
2013
Q4 | $884K | Buy |
14,671
+1,722
| +13% | +$93.7K | 0.01% | 1408 |
|
|
2013
Q3 | $787K | Buy |
12,949
+2,024
| +19% | +$144K | 0.01% | 1442 |
|
|
2013
Q2 | $732K | Buy |
+10,925
| New | +$491K | 0.01% | 1436 |
|
Other funds holding CLVS
N
PAI
HF
Metropolitan Life Insurance Company (MetLife)'s CLVS Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Clovis Oncology, Inc. (CLVS) in Q1 2022, closing a stake of 16,963 shares — an estimated $46K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in CLVS in Q2 2013 and held it in 35 quarters. The position peaked at $2.74M in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Clovis Oncology, Inc. position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 16,963 Clovis Oncology, Inc. shares in Q1 2022, an estimated $46K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 35 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Clovis Oncology, Inc. position peaked at $2.74M in Q2 2017.
- 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.